Table 3 Engineered CAR γδ T cell therapies
From: Gamma delta T cells and their immunotherapeutic potential in cancer
Year(s) | Technology | Cancer(s) | Effects/Status | Citation(s) |
|---|---|---|---|---|
2021 | Vδ1 T cells engineered using glypican-3–specific CAR and soluble IL-15 | Hepatocellular carcinoma | Successful preclinical in vitro and in vivo studies | |
2022 | CD20-directed CAR–Vδ1 T cells | Diffuse large B-cell, large B-cell, high-grade B-cell, mantle cell, and Burkitt lymphomas | Successful preclinical and phase 1 clinical trials | |
2023 | Increasing CD16 on Vδ2 T cells to enhance ADCC using anti-mesothelin CAR engineering with or without increased IL-15 expression | Ovarian cancer | Successful preclinical in vitro and in vivo studies (even better with increased IL-15 expression) | [210] |
2024 | Modification of G115 γδ TCR to recognize αvβ6-expressing tumor cells (CAR Vδ2 T cell) | Triple-negative breast and pancreatic cancers | Successful in vitro preclinical trial | |
2024 | γδ anti-CD22 CAR T cell (both Vδ1 and Vδ2) | B-cell acute lymphoblastic leukemia | Completely successful preclinical trials; now in clinical trials | [213] |